Researchers at Colorado State University have developed a metabolic biosignature—a unique molecular fingerprint found in blood—that detects early Lyme disease with 88% sensitivity and 95% specificity. This new test identifies more than 44 specific metabolites (small molecules) in the blood that are characteristic of early Lyme infection. The biosignature significantly outperforms the current CDC-recommended diagnostic approach, which only catches early Lyme disease 37-44% of the time. By analyzing these metabolites with advanced laboratory techniques, doctors can now identify patients with early Lyme disease more accurately and distinguish it from other similar conditions.
Lyme disease is the most common tick-borne illness in the United States and Europe, with an estimated 300,000 cases occurring annually in the US alone. Early diagnosis is critical for treatment success, yet current diagnostic methods fail to detect early-stage Lyme disease reliably. The CDC-recommended approach uses antibody testing, which is highly accurate for late-stage disease but detects only 29-40% of early infections because antibodies have not developed sufficiently yet. The characteristic skin rash (erythema migrans) used for clinical diagnosis is easily confused with other conditions like tick-bite reactions, STARI (southern tick-associated rash illness), and fungal infections, leading to misdiagnosis and delayed treatment.
This metabolic biosignature approach represents a change in thinking in Lyme disease diagnosis by identifying the actual biochemical signature of infection rather than relying solely on the immune system’s delayed antibody response or clinical appearance alone.
The metabolic biosignature was developed through advanced analysis of serum samples from patients with early Lyme disease, patients with other diseases, and healthy controls. Using liquid chromatography-mass spectrometry (LC-MS), researchers identified and quantified small molecule metabolites in the blood that distinguish early Lyme disease from non-Lyme conditions. The analysis revealed a signature of more than 44 metabolites that, when analyzed together using a statistical model, correctly identify early Lyme disease patients with 88% sensitivity (84-95% confidence interval) and 95% specificity. This represents a major improvement over the current CDC-recommended 2-tier serologic test, which achieves only 37-44% sensitivity in early-stage disease while maintaining similar specificity (95-100%). The metabolite pattern reflects the biological response to Borrelia burgdorferi infection early in disease progression before sufficient antibodies accumulate for antibody-based detection.
The test workflow involves collecting a blood serum sample, analyzing it with LC-MS instrumentation, and comparing the metabolite profile against the validated biosignature model. This approach is objective, quantitative, and not dependent on clinical interpretation of skin lesions or immune response timing, making it potentially more reliable for early diagnosis when clinical features are ambiguous or absent.
Available for Licensing
TRL: 4
John T Belisle
Claudia R Molins
Gary P Wormse
Steve Foster
Steve.Foster@colostate.edu
970-491-7100